Table 1 Core discovery summary.
Cancer types | Key genes | Molecular characteristics (mutation/ expression/ methylation) | Clinical association (prognosis/stage) | Potential mechanisms |
|---|---|---|---|---|
Cutaneous melanoma (SKCM) | DSCAM, DCC | The mutation rate was highest (60.14%), with DSCAM hotspot mutation E368K | High mutations are associated with malignancy | Mutations affect Ig domain and enhance EMT activity |
Head and neck squamous cell carcinoma (HNSC) | DCC, ROCK1 | Silencing DCC methylation, forming ROCK1-DCC fusion gene | Fusion genes are associated with increased invasiveness | Disrupts the NTN1 binding domain and promotes cell migration |
Renal clear cell carcinoma (KIRC) | UNC5D, NEO1 | Upregulation of UNC5D methylation (positively correlated with pathological stage) | Low UNC5D expression predicts poor prognosis | Methylation inhibits UNC5D and removes EMT inhibition |
Urinary bladder urothelial cancer (BLCA) | MCAM, UNC5B | High expression of MCAM and UNC5B are associated with poor prognosis | Immunotherapy effect is better in patients with low MCAM expression | MCAM regulates the immune microenvironment through macrophage infiltration |
